KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Intangibles: 2016-2024

Historic Intangibles for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Dec 2024 value amounting to $119.8 million.

  • Acadia Pharmaceuticals' Intangibles rose 5.78% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 5.78%. This contributed to the annual value of $119.8 million for FY2024, which is 82.90% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Intangibles stood at $119.8 million, which was up 82.90% from $65.5 million recorded in FY2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Intangibles peaked at $119.8 million during FY2024, and registered a low of $1.1 million during FY2020.
  • In the last 2 years, Acadia Pharmaceuticals' Intangibles had a median value of $92.6 million in 2023 and averaged $92.6 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Intangibles tumbled by 57.14% in 2020 and then spiked by 82.90% in 2024.
  • Yearly analysis of 3 years shows Acadia Pharmaceuticals' Intangibles stood at $1.1 million in 2020, then reached $65.5 million in 2023, then soared by 82.90% to $119.8 million in 2024.